摘要
目的:探讨利妥昔单抗联合CHOP方案对非霍奇金淋巴瘤的临床疗效。方法:48例非霍奇金淋巴瘤患者被随机分为两组,对照组行CHOP方案治疗;实验组在CHOP方案基础上,联合利妥昔单抗治疗;比较两组化疗效果及不良反应。结果:实验组中完全缓解(CR)11例,部分缓解(PR)8例,总有效率为79.2%;对照组中完全缓解(CR)7例,部分缓解(PR)6例,总有效率为54.2%;实验组的有效缓解率明显高于对照组,差异显著,具有统计学意义(P<0.05);但实验组不良反应的发生率与对照组无明显差异(P>0.05)。结论:利妥昔单抗联合CHOP方案治疗非霍奇金淋巴瘤的临床效果明显优于单一采用CHOP化疗方案,且联合用药并不会增加并发症的发生,适合于临床一线治疗。
Objective：To investigate the effect of rituximab combined with CHOP for non-Hodgkin＇s lymphoma .Methods：48 patients with non-Hodgkin＇s lymphoma were divided into experimental group （ 24 cases） and control group （24 cases） randomly.The patients in control group were treated with CHOP regi-men alone, and those in experimental group received rituximab combined with CHOP regimen.The response rate and adverse reaction were compared between two groups .Results： Patients got complete remission （CR） and partial remission （PR） were 11 cases and 8 cases, and total response rate was 79.2%in experi-mental group.And the numbers were 7 cases and 6 cases, and total response rate was 54.2% in control group.The therapeutic differences between two groups showed a statistical significance （P〈0.05）.But the rates of adverse reaction was similiar （ P〉0 .05 ） .Conclusion： Compared with CHOP regimen chemothera-py, rituximab combined with CHOP regimen shows better therapeutic effect without creasing the adverse re-action.
出处
《河北医学》
CAS
2014年第1期108-110,共3页
Hebei Medicine
